JP2020527134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527134A5 JP2020527134A5 JP2019572791A JP2019572791A JP2020527134A5 JP 2020527134 A5 JP2020527134 A5 JP 2020527134A5 JP 2019572791 A JP2019572791 A JP 2019572791A JP 2019572791 A JP2019572791 A JP 2019572791A JP 2020527134 A5 JP2020527134 A5 JP 2020527134A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- wound
- burn
- formulation
- mefp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000027418 Wounds and injury Diseases 0.000 claims 15
- 206010052428 Wound Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 5
- 238000011200 topical administration Methods 0.000 claims 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 4
- 241000237536 Mytilus edulis Species 0.000 claims 4
- 208000012641 Pigmentation disease Diseases 0.000 claims 4
- 230000035876 healing Effects 0.000 claims 4
- 235000020638 mussel Nutrition 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 208000003351 Melanosis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000006461 physiological response Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000019612 pigmentation Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 206010067982 Butterfly rash Diseases 0.000 claims 1
- 208000010445 Chilblains Diseases 0.000 claims 1
- 206010008528 Chillblains Diseases 0.000 claims 1
- 206010008570 Chloasma Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010014970 Ephelides Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010040844 Skin exfoliation Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 238000004299 exfoliation Methods 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960005127 montelukast Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 108010004563 mussel adhesive protein Proteins 0.000 claims 1
- 239000003988 mussel adhesive protein Substances 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CNPCT/CN2017/091819 | 2017-07-05 | ||
| CNPCT/CN2018/087058 | 2018-05-16 | ||
| CN2018087058 | 2018-05-16 | ||
| PCT/CN2018/094441 WO2019007356A1 (en) | 2017-07-05 | 2018-07-04 | TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527134A JP2020527134A (ja) | 2020-09-03 |
| JP2020527134A5 true JP2020527134A5 (enExample) | 2021-08-12 |
| JP7288404B2 JP7288404B2 (ja) | 2023-06-07 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572791A Active JP7288404B2 (ja) | 2017-07-05 | 2018-07-04 | モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11672792B2 (enExample) |
| EP (1) | EP3648767A4 (enExample) |
| JP (1) | JP7288404B2 (enExample) |
| KR (1) | KR102785243B1 (enExample) |
| CN (3) | CN113491696A (enExample) |
| AU (1) | AU2018295944B2 (enExample) |
| CA (1) | CA3068818A1 (enExample) |
| MA (1) | MA52924A (enExample) |
| MX (1) | MX2020000029A (enExample) |
| MY (1) | MY201703A (enExample) |
| SG (1) | SG11201911841PA (enExample) |
| TW (1) | TWI874298B (enExample) |
| WO (1) | WO2019007356A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| WO2020052677A1 (en) | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
| KR20210114962A (ko) * | 2019-01-10 | 2021-09-24 | 장인 무코케어 파마슈티컬 컴퍼니 리미티드 | 류코트리엔 수용체 길항제를 함유하는 신규 제제 |
| TW202120523A (zh) * | 2019-09-14 | 2021-06-01 | 大陸商江陰貝瑞森製藥有限公司 | 新肽 |
| AU2020397005A1 (en) * | 2019-12-02 | 2022-06-23 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| CA3160167A1 (en) * | 2019-12-02 | 2021-06-10 | Ming Gu | Peptides and their use in the treatment of inflammation |
| CA3166799A1 (en) | 2020-02-03 | 2021-08-12 | Vered Rosenberger | Topical montelukast formulations |
| US12233055B2 (en) | 2020-02-03 | 2025-02-25 | Taro Pharmaceutical Industries Ltd. | Topical Montelukast formulations |
| US20230372324A1 (en) | 2020-10-13 | 2023-11-23 | Diomed Developments Ltd. | Gel formulations comprising montelukast |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| JP2024530484A (ja) * | 2021-08-06 | 2024-08-21 | エンリティザ（シャンハイ）ファーマシューティカル カンパニー リミテッド | 免疫不全障害の新規治療 |
| CN116421547A (zh) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK282225B6 (sk) * | 1995-12-28 | 2001-12-03 | Welfide Corporation | Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku |
| US20030207932A1 (en) * | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| ZA200601089B (en) * | 2003-08-07 | 2007-05-30 | Hearlor Ltd | Pharmaceutical compositions and methods for accelerating wound healing |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) * | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (zh) * | 2006-11-16 | 2007-05-16 | 徐英权 | 孟鲁司特钠的颗粒剂型 |
| WO2008105803A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| WO2008106081A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| US20110124681A1 (en) * | 2008-05-06 | 2011-05-26 | Schlesinger Larry S | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (zh) * | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | 一种白三烯拮抗剂和抗组胺药组合物 |
| EP2799071B1 (en) * | 2010-06-16 | 2018-10-17 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast for the treatment of influenza and common cold |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| KR20130074766A (ko) | 2011-12-26 | 2013-07-04 | 에스케이케미칼주식회사 | 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름 |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| KR20150135339A (ko) * | 2013-03-13 | 2015-12-02 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도 |
| CN103655497B (zh) * | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
| US10369219B2 (en) * | 2014-08-04 | 2019-08-06 | Nitto Denko Corporation | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition |
| CN105769825A (zh) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | 一种孟鲁司特钠的口腔膜剂及其制备方法 |
| CN105878215A (zh) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途 |
| KR101892340B1 (ko) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
| CN104784157B (zh) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
| JP6778219B2 (ja) * | 2015-07-20 | 2020-10-28 | ジャンイン ベンクト アイ サミュエルソン インスティテュート オブ ライフ サイエンス カンパニー リミテッド | 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用 |
| WO2017011983A1 (zh) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 |
| JP6947756B2 (ja) * | 2016-02-22 | 2021-10-13 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 抗菌組成物およびその使用 |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| KR20210016365A (ko) * | 2018-05-28 | 2021-02-15 | 장인 우선 파마슈티컬 컴퍼니 리미티드 | 새로운 약제학적 용도 |
| WO2020052677A1 (en) * | 2018-09-14 | 2020-03-19 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates of montelukast and peptides |
| KR20210114962A (ko) * | 2019-01-10 | 2021-09-24 | 장인 무코케어 파마슈티컬 컴퍼니 리미티드 | 류코트리엔 수용체 길항제를 함유하는 신규 제제 |
-
2018
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/zh active Pending
- 2018-07-04 MY MYPI2020000043A patent/MY201703A/en unknown
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en not_active Ceased
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-04 MA MA052924A patent/MA52924A/fr unknown
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/ja active Active
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/zh active Active
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/zh active Pending
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/es unknown
- 2018-07-04 KR KR1020207003363A patent/KR102785243B1/ko active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-05 TW TW107123334A patent/TWI874298B/zh active
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/977,212 patent/US20250302818A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527134A5 (enExample) | ||
| US10568938B2 (en) | Mussel adhesive protein product and applications thereof in suppression of skin inflammations | |
| US20130052273A1 (en) | Pharmaceutical composition comprising periplaneta americana or its ethanol extract and a method of using the same for treating inflammations | |
| CN105142728A (zh) | 用于治疗表面创伤的组合物和方法 | |
| CN104981258A (zh) | 用于组织再生的组合物和方法 | |
| AR119031A1 (es) | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma | |
| US11696907B2 (en) | Wound healing composition | |
| DK2691103T3 (en) | METHOD FOR treating skin conditions | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| US10426803B2 (en) | Topical medicament for skin and mucosal injuries | |
| CN106456600B (zh) | 使用青蒿素及其衍生物治疗或预防脂溢性角化病 | |
| Al-lethie et al. | Evaluation of clinical recovery and healing of oral lesions by 3 different therapeutic regimens in cattle with foot and mouth disease (FMD) | |
| KR20200075335A (ko) | 피부병 치료제 | |
| CN117100818A (zh) | 一种治疗痔疮的外用膏剂及其制备方法 | |
| US20190000822A1 (en) | Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis | |
| Bachot et al. | Deep peels | |
| HK1254527A1 (zh) | 药物调配物和其用途 | |
| Ashurst | A Manual of Clinical Dermatology | |
| ALLEN | DISEASES OF THE SKIN. | |
| CN110403983A (zh) | 一种治疗痔疮的天然产物组合物及其制备方法 | |
| Thomas | Chronic Moniliasis | |
| Chakravorty et al. | Some Observations in the Use of Halogen Substituted Derivatives of Quinoline in Dermatological Practice | |
| Wise et al. | MANHATTAN DERMATOLOGIC SOCIETY | |
| HK1231780B (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
| HK1231780A1 (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof |